Trial Profile
A study of allogeneic mesenchymal precursor cells with corrective heart surgery in children under the age of 5 with hypoplastic left heart syndrome (HLHS)
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2017
Price :
$35
*
At a glance
- Drugs Rexlemestrocel-L (Primary)
- Indications Hypoplastic left heart syndrome
- Focus Therapeutic Use
- 12 Apr 2017 New trial record
- 03 Apr 2017 According to a Mesoblast media release, the United States Food and Drug Administration (FDA) has cleared the commencement of this trial. This trial is sponsored and funded by the Boston Childrens Hospital with support from Bulens and Capozzi Foundation and the Ethan Lindberg Foundation. Dr. Sitaram Emani is Principal Investigator of this study.